VIDEO: Destiny 04 Trial results have potential to be ‘practice changing’ for breast cancer
In this video, Kevin Kalinsky, MD, an associate professor of medicine at New York-Presbyterian Hospital/Columbia University Medical Center, discussed the Destiny 04 Trial presented at 39th Miami Breast Cancer Conference.
According to a press release, treatment with trastuzumab deruxtecan improved PFS and OS in patients with HER2-low unresectable and metastatic breast cancers compared with chemotherapy.
"This has the potential for being practice changing. At Miami Breast this time next year, I suspect our paradigm of treating patients with metastatic triple-negative breast cancer, as well as patients with metastatic hormone receptor-positive HER2-low disease, will shift," Kalinsky said.
Collapse
Read more about